Evidence map›Paper›PMID 36362861›Full record

ArticleLife (Basel, Switzerland)2022

Glycyrrhizin Inhibits SARS-CoV-2 Entry into Cells by Targeting ACE2.

Ming-Feng He, Jian-Hui Liang, Yan-Ni Shen, Jin-Wen Zhang, Ying Liu, Kuang-Yang Yang, Li-Chu Liu, Junyi Wang, Qian Xie, Chun Hu and 2 more

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025
    Review
  3. Antiviral Activity and Underlying Mechanism ofMolecules (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Licorice extract inhibits porcine epidemic diarrhea virusThe Journal of general virology · 2024
    Article
  6. Review
  7. International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Ming-Feng HeFoshan Hospital of Traditional Chinese Medicine, Foshan 528000, China.
Jian-Hui LiangCenter for Translation Medicine Research and Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Yan-Ni ShenCenter for Translation Medicine Research and Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Jin-Wen ZhangCenter for Translation Medicine Research and Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.ORCID 0000-0003-2828-3121
Ying LiuCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
Kuang-Yang YangFoshan Hospital of Traditional Chinese Medicine, Foshan 528000, China.
Li-Chu LiuFoshan Hospital of Traditional Chinese Medicine, Foshan 528000, China.
Junyi WangBluewood Associates Co., Ltd., Suzhou 215134, China.
Qian XieCenter for Translation Medicine Research and Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Chun HuKey Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.ORCID 0000-0003-2919-2870
Xun SongCollege of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.ORCID 0000-0002-2566-3519
Yan WangCenter for Translation Medicine Research and Development, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.ORCID 0000-0003-0671-7312
Chinese Academy of Sciences · CNFoshan Hospital of TCM · CNShenyang Pharmaceutical University · CNShenzhen Technology University · CN

Funding

Guangdong Basic and Applied Basic Research Fund 2020A1515011342National Natural Science Foundation of China 81903875, 82174033Project for High Efficiency and Developed Hospital at Foshan City 202200087, 202000189, 202200089Shenzhen Science and Technology Innovation Fund JCYJ20190807160601672
6 · The paper itself

Abstract

Coronavirus Disease 2019 (COVID-19) is a highly infectious and pathogenic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Early in this epidemic, the herbal formulas used in traditional Chinese medicine (TCM) were widely used for the treatment of COVID-19 in China. According to Venn diagram analysis, we found that

Indexed as

ACE2glycyrrhizinSARS-CoV-2spike protein RBD

Identifiers

PMID36362861
PMCPMC9697465
OpenAlexW4307291934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.